Adaptimmune Therapeutics Plc - ADR

NASDAQ:ADAP 4:00:00 PM EDT

1.06

-0.02 (-1.85%)

4:03:33 PM EDT: $1.06 0.00 (0.05%)

Market Cap (Intraday)	240.80M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$3.76 Million
Adjusted EPS	-$0.14

See more estimates

10-Day MA	$1.09
50-Day MA	$1.38
200-Day MA	$0.90

See more pivots

Adaptimmune Therapeutics Plc - ADR Stock, NASDAQ:ADAP

60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RX

United Kingdom

Phone: +44.1235.430000

Number of Employees: 449

http://www.adaptimmune.com

Description

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.